Profile data is unavailable for this security.
About the company
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
- Revenue in USD (TTM)31.76m
- Net income in USD-18.40m
- Incorporated2001
- Employees62.00
- LocationMolecular Templates Inc9301 Amberglen Blvd Ste 100AUSTIN 78729-1153United StatesUSA
- Phone+1 (512) 896-1555
- Fax+1 (302) 655-5049
- Websitehttps://mtem.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BioNexus Gene Lab Corp | 9.78m | -2.66m | 7.81m | 30.00 | -- | 0.8357 | -- | 0.7989 | -0.14 | -0.14 | 0.651 | 0.5289 | 1.01 | 8.55 | 5.80 | -- | -27.53 | -3.83 | -33.16 | -5.02 | 13.56 | 14.55 | -27.25 | -3.04 | 3.98 | -162.45 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
Transcode Therapeutics Inc | 0.00 | -17.06m | 7.95m | 10.00 | -- | 1.52 | -- | -- | -206.36 | -206.36 | 0.00 | 0.7893 | 0.00 | -- | -- | 0.00 | -264.82 | -133.14 | -721.90 | -181.26 | -- | -- | -- | -- | -- | -148.05 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
Allarity Therapeutics Inc | 0.00 | -20.94m | 8.01m | 5.00 | -- | -- | -- | -- | -599.34 | -599.34 | 0.00 | -18.88 | 0.00 | -- | -- | 0.00 | -100.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.02 | -- | -- | -- |
Psyence Biomedical Ltd | 0.00 | 1.52m | 8.08m | -- | -- | -- | 5.33 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
Universe Pharmaceuticals Inc | 32.31m | -6.16m | 8.09m | 225.00 | -- | 0.2036 | -- | 0.2505 | -1.70 | -1.70 | 8.91 | 10.91 | 0.5727 | 7.93 | 2.50 | 143,594.40 | -10.92 | 5.31 | -14.34 | 7.07 | 31.93 | 46.26 | -19.08 | 6.25 | 2.43 | -28.05 | 0.1218 | 0.00 | -19.52 | 2.53 | 29.46 | -- | -21.17 | -- |
Enzolytics Inc | 0.00 | -119.19k | 8.29m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
Nymox Pharmaceutical Corp | 0.00 | -4.87m | 8.39m | 3.00 | -- | -- | -- | -- | -0.0536 | -0.0536 | 0.00 | -0.0204 | 0.00 | -- | -- | -- | -255.75 | -264.40 | -- | -464.48 | -- | -- | -- | -13,001.67 | -- | -42.44 | -- | -- | -- | -- | 47.55 | -- | -- | -- |
Molecular Templates Inc | 31.76m | -18.40m | 8.59m | 62.00 | -- | 1.19 | -- | 0.2705 | -4.36 | -4.36 | 5.98 | 1.09 | 0.6014 | -- | 19.55 | 512,306.40 | -34.83 | -51.78 | -54.80 | -73.14 | -- | -- | -57.92 | -228.33 | -- | -52.11 | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
Protext Mobility Inc | 750.00 | -2.21m | 8.79m | 4.00 | -- | -- | -- | 11,721.63 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 8.89m | 233.00 | 0.0596 | 0.0009 | 2.30 | 0.1256 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
Bon Natural Life Ltd | 29.52m | 4.60m | 9.25m | 96.00 | 0.4669 | 0.0771 | 1.68 | 0.3134 | 4.99 | 4.99 | 32.10 | 30.23 | 0.7045 | 15.27 | 5.19 | 307,524.60 | 10.86 | 14.04 | 13.69 | 20.68 | 29.94 | 30.00 | 15.42 | 17.62 | 2.41 | 30.54 | 0.0955 | 0.00 | -1.29 | 22.32 | -26.32 | 83.09 | -6.70 | -- |
ABVC Biopharma Inc | 25.37k | -12.62m | 9.32m | 16.00 | -- | 1.18 | -- | 367.43 | -2.37 | -2.37 | 0.0043 | 0.7284 | 0.002 | -- | 0.0673 | 1,585.63 | -103.15 | -103.38 | -189.31 | -231.54 | -854.20 | 76.25 | -51,218.29 | -2,019.89 | -- | -3.19 | 0.1853 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
Pacific Software Inc | 0.00 | -77.46k | 9.36m | 0.00 | -- | 0.3008 | -- | -- | -0.1832 | -0.1832 | 0.00 | 0.7646 | 0.00 | -- | -- | -- | -26.19 | -620.48 | -66.38 | -- | -- | -- | -- | -- | -- | -6.29 | 0.00 | -- | -- | -- | -13.29 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Bellevue Asset Management AGas of 31 Mar 2024 | 1.03m | 19.16% |
BVF Partners LPas of 31 Mar 2024 | 522.24k | 9.72% |
SilverArc Capital Management LLCas of 31 Mar 2024 | 354.61k | 6.60% |
Adage Capital Management LPas of 31 Mar 2024 | 257.20k | 4.79% |
Caxton Corp.as of 31 Mar 2024 | 136.87k | 2.55% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 125.61k | 2.34% |
Monashee Investment Management LLCas of 31 Mar 2024 | 105.49k | 1.96% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 39.64k | 0.74% |
Geode Capital Management LLCas of 31 Mar 2024 | 37.43k | 0.70% |
Renaissance Technologies LLCas of 31 Mar 2024 | 20.05k | 0.37% |